NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145.4 USD | +1.48% |
|
+4.75% | +41.81% |
| 28/06 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 28/06 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
| Sales 2024 * | 29TCr 4.19TCr 3,49300Cr | Sales 2025 * | 35TCr 5.06TCr 4,22100Cr | Capitalization | 4,46000Cr 64TCr 53,41900Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 10TCr 1.5TCr 1,24900Cr | Net income 2025 * | 13TCr 1.84TCr 1,53200Cr | EV / Sales 2024 * | 15.4 x |
| Net Debt 2024 * | 2.26TCr 324.47Cr 27TCr | Net cash position 2025 * | 592.89Cr 85Cr 7.1TCr | EV / Sales 2025 * | 12.6 x |
| P/E ratio 2024 * |
43.3
x | P/E ratio 2025 * |
35.2
x | Employees | 66,015 |
| Yield 2024 * |
1.17% | Yield 2025 * |
1.44% | Free-Float | 70.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +1.48% | ||
| 1 week | +4.75% | ||
| Current month | +8.34% | ||
| 1 month | +6.68% | ||
| 3 months | +14.91% | ||
| 6 months | +39.29% | ||
| Current year | +41.81% |
1 week
137.65
149.55
1 month
131.36149.55
Current year
100.50149.55
1 year
74.70149.55
3 years
40.84149.55
5 years
23.76149.55
10 years
15.54149.55
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/91/01 | |
| Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 19/15/19 |
Helge Lund
CHM | Chairman | 61 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/24/28 | 145.4 | +1.48% | 3,193 |
| 27/24/27 | 143.2 | -1.74% | 23,266 |
| 26/24/26 | 145.8 | -2.13% | 41,718 |
| 25/24/25 | 149 | +4.53% | 5,567 |
| 24/24/24 | 142.5 | +2.70% | 1,697 |
Delayed Quote OTC Markets, June 29, 2024 at 01:28 am IST
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 82TCr | |
| -6.75% | 35TCr | |
| +13.56% | 33TCr | |
| +10.68% | 30TCr | |
| +16.57% | 24TCr | |
| +2.04% | 23TCr | |
| +13.31% | 22TCr | |
| +8.48% | 17TCr | |
| -2.81% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- NONO.F Stock
